Duarte Tatiana, Gonçalves Sara, Sá Catarina, Marinheiro Rita, Fonseca Marta, Farinha José, Rodrigues Rita, Seixo Filipe, Parreira Leonor, Caria Rui
Serviço de Cardiologia, Centro Hospitalar de Setúbal, Setúbal, Portugal.
Serviço de Cardiologia, Centro Hospitalar de Setúbal, Setúbal, Portugal.
Rev Port Cardiol (Engl Ed). 2019 Feb;38(2):105-111. doi: 10.1016/j.repc.2018.05.018. Epub 2019 Mar 15.
In iatrogenic or potentially reversible bradyarrhythmia, drug discontinuation or metabolic correction is recommended before permanent cardiac pacemaker (PM) implantation. These patients often have conduction system disease and there are few data on recurrence or the need for a permanent PM.
To analyze the need for PM implantation in patients with iatrogenic bradyarrhythmia or bradyarrhythmia associated with other potentially reversible causes.
We assessed consecutive symptomatic patients admitted to the emergency department with a primary diagnosis of bradyarrhythmia (atrioventricular [AV] node disease - complete or second-degree AV block (AVB) [CAVB: 2nd-degree AVB - 2:1], sinus bradycardia [SB] and atrial fibrillation [AF] with slow ventricular response [SVR]) in the context of iatrogenic causes or metabolic abnormalities. We determined the percentage of patients who required PM implantation.
We studied 153 patients (47% male) admitted for iatrogenic or potentially reversible bradyarrhythmia. Diagnoses were SB 16%, CAVB 63%, second-degree AVB 12%, and AF with SVR 10%. Eighty-five percent of patients were under negative chronotropic therapy, 3% had hyperkalemia and 12% had a combined etiology. After correction of the cause, 55% of patients (n=84) needed a PM. In these patients the most common type of bradyarrhythmia was CAVB, in 77% (n=65) patients.
In a high percentage of patients with bradyarrhythmia associated with a potentially reversible cause, the arrhythmia recurs or does not resolve during follow-up. Patients with AV node disease constitute a subgroup with a higher risk of recurrence who require greater vigilance during follow-up and should be considered for PM implantation after the first episode.
对于医源性或潜在可逆性缓慢性心律失常患者,建议在植入永久性心脏起搏器(PM)之前停用药物或纠正代谢异常。这些患者通常患有传导系统疾病,关于复发情况或永久性PM需求的数据较少。
分析医源性缓慢性心律失常或与其他潜在可逆性病因相关的缓慢性心律失常患者植入PM的必要性。
我们评估了因医源性病因或代谢异常而以缓慢性心律失常(房室[AV]结疾病 - 完全性或二度AV阻滞[CAVB:二度AV阻滞 - 2:1]、窦性心动过缓[SB]以及伴有缓慢心室反应[SVR]的心房颤动[AF])为主诊入住急诊科的连续有症状患者。我们确定了需要植入PM的患者百分比。
我们研究了153例因医源性或潜在可逆性缓慢性心律失常入院的患者(47%为男性)。诊断包括SB占16%、CAVB占63%、二度AV阻滞占12%以及伴有SVR的AF占10%。85%的患者接受负性变时性治疗,3%有高钾血症,12%有合并病因。病因纠正后,55%的患者(n = 84)需要植入PM。在这些患者中,最常见的缓慢性心律失常类型是CAVB,占77%(n = 65)患者。
在很大比例的与潜在可逆性病因相关的缓慢性心律失常患者中,心律失常在随访期间复发或未得到缓解。AV结疾病患者构成复发风险较高的亚组,在随访期间需要更高的警惕性,并且在首次发作后应考虑植入PM。